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GVHD IN MULTI-VISCERAL TRANSPLANT RECIPIENTS
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Introduction: GVHD is a rare but life-threatening complication
following solid organ transplant with high (.50%) mortality.
Transfer of imunologically competent cells into an immunosup-
pressed host during solid organ transplantation results in detect-
able levels of donor T cell chimerism in recipient peripheral
blood. During multi-visceral transplantation, lymphocytes are
transferred with the graft into an immunocompromised host in
the setting of minimal HLA matching. This scenario of active do-
nor lymphocytes in an immune compromised host in the setting of
HLA mismatch at all or most loci facilitates the development of
GVHD.
Hypothesis:We hypothesize that a small level of donor T cell chi-
merism (0-5%) will increase recipient tolerance of the donor graft
and increased donor T cell chimerism (.15%) will increase the in-
cidence and severity of GVHD following solid organ transplanta-
tion.
Methods:Data from all children treated with multi-visceral trans-
plantation at Cincinnati Children’s Hospital Medical Center from
2003 to 2009 were analyzed retrospectively to identify the fre-
quency of donor T-cell chimerism, and the frequency of clinical
GVHD. Demographic data, transplant characteristics, donor char-
acteristics, and donor T cell chimerism, and GVHD were ana-
lyzed.
Results: A total of 32 patients were included in the study. Median
age at time of transplantation was 2.62 years. The incidence of
GVHD was 19% (6 of 32 patients). Grade I-II GVHD was ob-
served in 4 patients and grade III-IV GVHD was observed in 2 pa-
tients. All patients with GVHD demonstrated skin involvement. A
total of 11 patients had donor T cell chimerism data available. Do-
nor T cell chimerism was low (0-5%) in 18%, moderate (5-15%) in
9%, and high (.15%) in 73% of patients. 100% of patients with
GVHD had detectable levels of donor T cells. Increased (.15%)
donor T cell chimerism was noted in 5 of 6 (83%, p\0.05) pa-
tients with GVHD following multivisceral transplantation. Three
of six (50%) patients with GVHD are surviving after treatment
with immune suppression.
Conclusions: Patients with moderate to increased levels of donor T
cell chimerism are at increased risk of developing GVHD following
transplantation of lymphocyte rich solid organs. Patients who de-
velop GVHD commonly have skin manifestations. Patients with
a new rash following solid organ transplant with detectable levels
of donor T cell chimerism should receive a skin biopsy to evaluate
for GVHD.432
INDUCED STERILE SEROSAL EFFUSION BY ACUTE GVHD AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
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Sterile serosal effusion after allo-HSCT has been described, but
it is still a poorly characterized entity. We describe a case of mas-
sive pleural effusion in a 10 years old male that was submitted to
an identical sibling allo-PBHSCT for acute biphenotype leukemia.
The conditioning was the BuCyMel. He received 12,9106
CD34+ cells/kg. The GVHD prophylaxis was CSA and MTX.
On D + 17, the patient developed moderated cutaneous and intes-
tinal aGVHD treated with high dose steroid for 6 weeks with
complete response to therapy. On D + 59, he developed positive
antigenemia for CMV without any signs of disease. He was treated
with gancyclovir for 4 weeks until the steroid was tapered. He be-
came antigenemia negative since the second week of treatment.
On D + 65, he was diagnosed with hemorrhagic cystitis and apositive PCR for polyomavirus was detected on blood and urine.
Cydofovir was initiated to treat him. On D + 69, he related dysp-
neia and a massive bilateral pleural effusion was detected by chest
 ray. He didn’t show any other symptoms of GVHD at this time.
The echo showed a mild pericardial effusion with 62% ejection
fraction and the ultrasound of the abdomen showed a moderated
ascites. The renal function and albumin were normal, proteinuria
and antinucleolar antibody were negative. He was submitted to
a bilateral pleural drainage with pleural and lung biopsy that
showed thickening of the conjunctive tissue of the pleura, and
rare macrophages and/or endothelial cells with a high hyperchro-
matic nuclei suggestive of cytopathic viral action in the lung. The
IMF and PCR analyses were negative for CMV and polyomavirus
in the tissues biopsies and in the transudate pleural effusion. Since
the patient was already in use of cydofovir without improvement
of the drainaged effusions, we decided to restart with prednisone
2 mg/kg/d. The patient presented with prompt clinical response
after steroids and became free of drainage on D + 91. In this
case, we don’t know if the effusions were caused by CMV or poly-
oma, since these virus were negative in the biopsies and effusions.
Moreover, we can’t exclude that these effusions were not a manifes-
tation of acute GVHD triggered by the presence of CMV or poly-
oma infections, since the patient had an optimal response to
steroids. In conclusion: recently, some cases of serosal effusions
have been related to acute GVHD. However, this relationship
needs to be more studied to be associated definitively to acute
GVHD, viral infections or both.433
STEROID-SENSITIVE UPPER ACUTE GASTROINTESTINAL ACUTE GRAFT-
VERSUS-HOSTDISEASEDIAGNOSEDWITHOUTTHEHISTOPATHOLOGICAL
FINDING
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Introduction:The gastrointestinal (GI) tract is the major target site
of the acute graft-versus-host disease (aGVHD), however, it and the
degree of severity in which is not diagnosed with easy.
Patients andMethods: Sixty-seven patients (pts) withHSCT in our
center from 2006 to 2009were evaluated. Among them, 34 acutemy-
elogenous leukemia, 9 acute lymphoblastic leukemia, 2 chronic my-
elogenous leukemia, 11 myelodysplastic syndrome, and 11
malignant lymphoma were diagnosed. Eight peripheral bloods, 50
bone marrows and 10 cord bloods were transplanted from 14 related
donors and 54 unrelated donors with the conditioning treatments,
including 52 myeloablative and 15 non-myeloablative regimens.
The numbers of HLA-mismatch locus were serologically 8 at 4/6
or less than, 8 at 5/6, and genetically 13 at 4/6 or less than and 16
at 5/6. GVHD prophylaxis included FK506 plus short-term metho-
trexate (sMTX) for 53 pts and cyclosporine plus sMTX for 14 pts.
When nausea and vomiting started after the weakness of regimen-re-
lated toxicities, the endoscopic finding and the biopsy were operated.
As soon as possible, steroid at a dose of 1.0 mg/kg per day firstly
was administered for the treatment of upperGI-aGVHDat the point
of clinical diagnosis of it.
Results: Seven patients were applicable, but they had notable fea-
tures in their background. Four of them had stage 1 lower GI-
aGVHD and 4 of them complicated with stage 1 to 2 skin
aGVHD, therefore the final grades of their aGVHD were from
0 to 2, not seriously. The symptoms started at the mean of 19.4
(13-26) days after HSCT, and the endoscopic finding and the treat-
ment was administered at the mean of 26.3 (21-35) days and 28.0
(21-34) days after the symptoms. Due to a clinical observation,
each of the diagnosis and the treatment to upper GI-aGVHD
were delayed for 5.8 days and 8.6 days. All of 6 patients examined
with the gastric biopsy were not histopathologically confirmed, but
interestingly, five among of them except for one at the non-remis-
sion state were quickly recovering. There were not pts with relapse
after the steroid-therapy.
Conclusion: We consider that the diagnosis of upper GI-aGVHD
based on the histopathological finding is in part difficult, but the re-
sponse to the treatment with steroid in mostly is sensitive and safety.
